Financial Performance Summary

Morepen Laboratories reported its highest-ever quarterly financial performance for Q1 FY27 (quarter ended June 30, 2026).

Key Financial Metrics:

  • Revenue: ₹575.31 Crore, up 34% Year-over-Year (YoY)
  • EBITDA: ₹87.72 Crore, up 207% YoY
  • EBITDA Margin: 15.25%, significantly improved from 6.65% in Q1 FY26
  • PAT (Profit After Tax): ₹56.35 Crore, up 394% YoY

Business Segment Performance

API Business:

  • Recorded 31% growth overall
  • API exports grew 42% YoY
  • Supported by healthy recovery in base business, improved product mix, customer prioritization, and better operating discipline

Medical Devices Business:

  • Recorded 19% growth during the quarter
  • Focused on chronic-care categories including blood glucose meters, blood pressure monitors, consumables
  • Reported installed base of 20 million blood glucose meters
  • Annual strip scale of 500 million strips, supporting recurring consumables revenue

Export Performance:

  • Export revenue grew 111% YoY

CDMO Business Update

The company achieved a major strategic milestone with its previously announced ₹825 Crore CDMO mandate entering full scale commercialization phase:

  • ₹58 Crore worth of commercial CDMO dispatches completed during Q1 FY27
  • Marks commercial validation of the Company's Morepen 2.0 strategy
  • Represents shift from traditional commodity APIs toward innovation-led manufacturing and long-duration CDMO partnerships

Capacity Expansion Plans

  • Manufacturing capacity expansion planned in phases
  • Capacity roadmap envisages expansion up to 1,200 KL by FY30
  • Supports larger global CDMO opportunities

Strategic Focus Areas

The company is building CDMO-led growth around four strategic pillars:

1. Capacity augmentation

2. Global partnerships

3. Capability scale-up

4. Global compliance

Technology roadmap includes:

  • Small molecules
  • Process chemistry
  • Complex chemistry
  • Advanced intermediates
  • Process intensification
  • High-potency manufacturing
  • Specialty APIs
  • Difficult-to-make molecules
  • Future expansion into peptides, oligos, and new modalities

Management Commentary

Mr. Sushil Suri, Chairman & Managing Director:

  • Q1 FY27 marks important validation of Morepen's transformation journey
  • Company delivered highest-ever quarterly revenue and strong profitability improvement
  • Shift from transaction-led API business to manufacturing-led platform with long-duration global partnerships
  • API profitability recovering, exports growing strongly
  • Medical Devices continuing to scale as second growth engine

Near-term priorities:

  • Commercial CDMO supplies
  • API profitability recovery
  • Capacity utilisation

Medium-term focus:

  • Capacity augmentation
  • New customer opportunities
  • Operating leverage

Long-term aim:

  • Build innovation-led manufacturing platform
  • Anchored in global partnerships
  • Sustainable value creation

Company Background

Morepen Laboratories Limited is a vertically integrated pharmaceutical and healthcare company with:

  • Over four decades of API manufacturing experience
  • Globally approved facilities
  • Exports across more than 90 countries
  • Established leadership positions across key APIs
  • Regulated-market compliant manufacturing infrastructure
  • Strong global quality track record

The company is expanding from traditional API business into innovation-led manufacturing platform focused on:

  • Long-duration supply contracts
  • CDMO partnerships
  • Process scale-up
  • Regulated-market customer programs
  • Global pharmaceutical partnerships